Clindesse

Manufacturer
Padagis Israel Pharmaceuticals Ltd
Effective date
2025-01-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
12
Source
full-release
Hydrated at
2026-05-31 21:54:35

Label at a glance#

ProductClindesse
Active ingredientCLINDAMYCIN PHOSPHATE
Label structure18 sections

Indications and uses

Clindesse is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis) in non-pregnant women.

Dosage and administration

The recommended dose is the complete contents of a single pre-filled applicator containing 5 g of Clindesse cream administered once intravaginally at any time of the day. Not for ophthalmic, dermal, or oral use.

Storage and handling

Clindesse (clindamycin phosphate) Vaginal Cream, 2%, is available in cartons containing one single-dose, pre-filled disposable applicator (NDC 45802-042-01). Each applicator delivers approximately 5 g of vaginal cream containing approximately 100 mg of clindamycin. Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature.] Avoid heat above 30°C (86°F).

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

1.1 Treatment of Bacterial Vaginosis

SPL UNCLASSIFIED SECTION

Clindesse is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis) in non-pregnant women.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dose is the complete contents of a single pre-filled applicator containing 5 g of Clindesse cream administered once intravaginally at any time of the day.

Not for ophthalmic, dermal, or oral use.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Clindesse is an intravaginal cream containing clindamycin phosphate 2%. Each pre-filled, single-dose applicator delivers approximately 5 g of cream containing approximately 100 mg of clindamycin.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

4.1 Hypersensitivity

SPL UNCLASSIFIED SECTION

Clindesse is contraindicated in individuals with a history of hypersensitivity to clindamycin or other lincosamides. Reported reactions to other formulations of clindamycin include rashes, urticaria, erythema multiforme, and anaphylactoid reactions [see Adverse Reactions (6.2)].

4.2 History of Bowel Disease

SPL UNCLASSIFIED SECTION

Clindesse is contraindicated in patients with regional enteritis, ulcerative colitis, or a history of Clostridioides difficile-associated diarrhea.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Clostridioides difficile-Associated Diarrhea (CDAD)

SPL UNCLASSIFIED SECTION

Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated [see Adverse Reactions (6.2)].

5.2 Use with Condoms and Vaginal Contraceptive Diaphragms

SPL UNCLASSIFIED SECTION

This cream contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, the use of such barrier contraceptives is not recommended concurrently or for 5 days following treatment with Clindesse. During this time period, condoms may not be reliable for preventing pregnancy or for protecting against transmission of HIV and other sexually transmitted diseases [see Use in Specific Populations (8.3)].

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

6.1 Clinical Study Experience

SPL UNCLASSIFIED SECTION

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to Clindesse in 368 patients. Clindesse was studied in three clinical studies: placebo-controlled (n=85), active-controlled (n=263), and single-arm (n=20). The population was female, aged 18 to 78, who were diagnosed with bacterial vaginosis. Patient demographics in the trials were 51% Caucasian, 36% Black, 10% Hispanic, and 3% Asian, other or unknown. All patients received 100 mg clindamycin phosphate cream intravaginally in a single dose.

Of the 368 women treated with a single dose of Clindesse, 1.6% of the patients discontinued therapy due to adverse reactions. Adverse reactions occurred in 126 of 368 patients (34%) treated with Clindesse and in 32 of 85 patients (38%) treated with placebo.

Adverse reactions occurring in ≥2% of patients receiving Clindesse in the placebo-controlled clinical trial are shown in Table 1.

Table 1. Adverse Reactions Occurring in ≥2% of Clindesse-Treated Patients and at a Higher Rate than Placebo-Treated Patients

Adverse Reactions

Clindesse
N=85
n (%)

Placebo
N=85
n (%)

Vaginosis fungal NOS*

12 (14)

7 (8)

Headache NOS

6 (7)

2 (2)

Back Pain

4 (5)

1 (1)

Constipation

2 (2)

0 (0)

Urinary tract infection NOS

2 (2)

0 (0)

N = number of patients in intent-to-treat population

n (%) = number and percentage of patients with reported adverse reaction

NOS = not otherwise specified

  • *The use of clindamycin may result in the overgrowth of non-susceptible fungal organisms in the vagina and may require antifungal treatment
  • Other reactions reported by <1% of those women treated with Clindesse include:
  • Dermatologic: Pruritic rash
  • Gastrointestinal: Diarrhea, vomiting
  • General: Fatigue
  • Immune System: Hypersensitivity
  • Nervous System: Dizziness
  • Reproductive System: Dysfunctional uterine bleeding, dysmennorrhea, intermenstrual bleeding, pelvic pain, vaginal burning, vaginal irritation, vulvar erythema, vulvitis, vulvovaginal discomfort, vulvovaginal dryness, vulvovaginitis

6.2 Other Clindamycin Formulations

SPL UNCLASSIFIED SECTION

Clindesse affords minimal peak serum levels and systemic exposure (AUCs) of clindamycin compared to an oral or intravenous dose of clindamycin [see Clinical Pharmacology (12.3)]. Data from well-controlled trials directly comparing clindamycin administered orally to clindamycin administered vaginally are not available.

The following additional adverse reactions and altered laboratory tests have been reported with the oral or parenteral use of clindamycin:

Gastrointestinal: Abdominal pain, esophagitis, nausea, Clostridioides difficile-associated diarrhea [see Warnings and Precautions (5.1)].

Hematopoietic: Transient neutropenia (leukopenia), eosinophilia, agranulocytosis, and thrombocytopenia have been reported. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of these reports.

Hypersensitivity Reactions: Maculopapular rash, vesiculobullous rash, and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Cases of erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. A few cases of anaphylactoid reactions have been reported.

Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.

Musculoskeletal: Cases of polyarthritis have been reported.

Renal: Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances.

Immune System: Drug reaction with eosinophilia and systemic symptoms (DRESS) cases have been reported.

6.3 Postmarketing Experience

SPL UNCLASSIFIED SECTION

The following adverse reactions have been identified during postapproval use of Clindesse. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Dermatologic: Rash

Gastrointestinal: Hematochezia

Reproductive System: Vaginal erythema, vulvovaginal pruritis, vaginal discharge, vaginal swelling, vaginal bleeding, vaginal pain

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

No formal drug interaction studies have been conducted for Clindesse.

7.1 Neuromuscular Blocking Agents

SPL UNCLASSIFIED SECTION

Orally or intravenously administered clindamycin has neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

Clindesse has not been studied in pregnant women. The systemic exposure (based on AUC and Cmax) of Clindesse administered intravaginally is substantially lower than clindamycin administered intravenously [see Clinical Pharmacology (12.3)]; therefore, maternal use is not likely to result in significant fetal exposure to the drug. Available data from published observational studies and randomized controlled trials over decades of use with other clindamycin products during pregnancy have not identified an increased risk of major birth defects, miscarriage, or other adverse maternal and fetal outcomes.

In animal reproduction studies, no adverse developmental outcomes were observed in pregnant rats and mice administered oral doses of clindamycin at up to 600 mg/kg/day (58 and 29 times, respectively, the recommended human dose based on a body surface area comparison) (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Reproduction studies have been performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (58 and 29 times, respectively, the recommended human dose based on body surface area comparisons) and have revealed no evidence of harm to the fetus due to clindamycin.

8.2 Lactation

LACTATION SECTION

Risk Summary

The systemic exposure (based on AUC and Cmax) of Clindesse is substantially lower than intravenous administration of clindamycin [see Clinical Pharmacology (12.3)]; therefore, adverse effects on the breastfed infant are not expected from transfer of clindamycin into breastmilk. There are no data on the effect of clindamycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Clindesse and any potential adverse effects on the breastfed infant from Clindesse or from the underlying maternal condition.

8.3 Females and Males of Reproductive Potential

FEMALES & MALES OF REPRODUCTIVE POTENTIAL SECTION

Contraception

Clindesse contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, the use of such barrier contraceptives is not recommended concurrently or for 5 days following treatment with Clindesse. During this time period, condoms may not be reliable for preventing pregnancy or for protecting against transmission of HIV and other sexually transmitted diseases [see Warnings and Precautions (5.2)].

8.4 Pediatric Use

PEDIATRIC USE SECTION

The safety and efficacy of Clindesse in the treatment of bacterial vaginosis in post-menarchal females have been established on the extrapolation of clinical trial data from adult women. The safety and efficacy of Clindesse in pre-menarchal females have not been established.

8.5 Geriatric Use

GERIATRIC USE SECTION

Clinical studies with Clindesse did not include sufficient numbers of subjects 65 years of age or older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

10 OVERDOSAGE

OVERDOSAGE SECTION

Vaginally applied clindamycin phosphate vaginal cream 2% could be absorbed in sufficient amounts to produce systemic effects [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)].

11 DESCRIPTION

DESCRIPTION SECTION

Clindamycin phosphate, a lincosamide, is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The chemical name for clindamycin phosphate is methyl 7-chloro- 6,7,8-trideoxy-6-(1-methyl- trans- 4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-(alpha)-D-galacto-octopyranoside 2-(dihydrogen phosphate). It has a molecular weight of 504.96, and the molecular formula is C18H34CIN2O8PS. The structural formula is represented below:

Structural Formula
Structural Formula

Clindesse is a semi-solid, white cream, which contains clindamycin phosphate, USP, at a concentration equivalent to 20 mg clindamycin base per gram. The cream also contains edetate disodium, glycerol monoisostearate, lecithin, methylparaben, microcrystalline wax, mineral oil, polyglyceryl-3-oleate, propylparaben, purified water, silicon dioxide and sorbitol solution.

Clindesse does not comply with the pH test of the USP monograph for clindamycin phosphate vaginal cream.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Clindamycin is an antibacterial drug [see Clinical Pharmacology, Microbiology (12.4)].

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Following a single intravaginal application of Clindesse cream to 20 healthy women, the mean (range) AUC0-inf and Cmax estimates were 175 (38.6 to 541) ng/mL•hr and 6.6 (0.8 to 39) ng/mL, respectively. The mean Cmax of clindamycin for Clindesse was approximately 0.3%, 0.1%, and 7.6% of that observed after the administration of a 150 mg Cleocin oral capsule (2.5 mcg/mL), a 600 mg Cleocin intravenous injection (10.9 mcg/mL), and a single dose of 100 mg of Cleocin Vaginal Cream (86.5 ng/mL), respectively. The peak serum concentration of clindamycin was attained approximately 20 hours post dosing for Clindesse.

12.4 Microbiology

MICROBIOLOGY SECTION

Mechanism of Action

Clindamycin inhibits bacterial protein synthesis at the level of the bacterial ribosome. The antibiotic binds preferentially to the 50S ribosomal subunit and affects the process of peptide chain initiation. Although clindamycin phosphate is inactive in vitro, in vivo hydrolysis converts this compound to the antibacterially active clindamycin.

Activity In Vitro

Clindamycin is an antibacterial agent active in vitro against most strains of the following organisms that have been reported to be associated with bacterial vaginosis:

Bacteroides spp.

Gardnerella vaginalis

Mobiluncus spp.

Mycoplasma hominis

Peptostreptococcus spp.

Standard methodology for the susceptibility testing of the potential bacterial vaginosis pathogens has not been defined. Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of bacterial vaginosis [see Clinical Studies (14)].

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames test. Both tests were negative. Fertility studies in rats treated orally with up to 300 mg/kg/day (29 times the recommended human dose based on body surface area comparisons) revealed no effects on fertility or mating ability.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

Two clinical studies were conducted to evaluate the efficacy of Clindesse for the treatment of bacterial vaginosis. A clinical diagnosis of bacterial vaginosis was defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells.

In a randomized, double-blind, placebo-controlled, clinical study involving 144 non-pregnant female patients aged 18 to 64 with a baseline Nugent score ≥4, Clindesse demonstrated statistically significantly higher cure rates over placebo as measured by therapeutic cure, clinical cure, and Nugent score cure (Table 2) assessed at 21-30 days after administration of the drug. Therapeutic cure was a composite endpoint which required both clinical cure and Nugent score cure. Clinical cure required normal vaginal discharge, vaginal pH < 4.7, < 20% clue cells on wet mount preparation, and negative “whiff” test (detection of amine odor on addition of 10% KOH solution to sample of the vaginal discharge). A Nugent score of 0-3 was considered a Nugent score cure. The Nugent scoring is based on microscopic examination of the Gram’s stained vaginal smears for quantification of specific bacterial morphotypes. Cure rates were consistently higher for Clindesse compared to placebo for the following demographic subsets: age, race, height, weight, sexual behavior, and recalcitrant infection status.

Table 2. Efficacy of Clindesse for Treatment of Bacterial Vaginosis in a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Outcome

Clindesse
N=78
% Cure

Placebo
N=66
% Cure

Treatment
Difference† (%)

[97.5% Confidence Interval]

Therapeutic Cure

29.5

3.0

26.5 [14.0, 39.0]

Clinical Cure

41.0

19.7

21.3 [4.7, 38.0]

Nugent Score Cure

44.9

6.1

38.8 [24.6, 53.1]

N = number of patients in treatment group (modified intent-to-treat population defined as all subjects randomized who received at least one dose of study medication, and who had a baseline Nugent score of at least 4)

†Treatment difference = Clindesse minus placebo cure rates

In a second controlled clinical study involving 432 patients aged 18 to 78 with a baseline Nugent score of ≥4, 221 women self-administered a single dose of Clindesse, and 211 women self-administered a single daily dose of a formulation of clindamycin vaginal cream for 7 days. A single dose of Clindesse was shown to be similar to 7 daily doses of the clindamycin vaginal cream for treatment of bacterial vaginosis as measured by therapeutic cure, clinical cure or Nugent score cure assessed at 21-30 days after administration of the drug in the modified intent-to-treat population (Table 3) and for the per protocol population (Table 4). The study endpoints were identical to those described above for the placebo-controlled study. Statistical analyses did not reveal any significant differences when controlling for the following demographic variables: age, race, height, weight, sexual behavior, and recalcitrant infection status.

The cure rates reported in the clinical studies with Clindesse were based on resolution of 4 out of 4 Amsel criteria and a Nugent score of < 4, while the criteria for cure in previous clinical studies with the clindamycin vaginal cream were based solely on resolution of 2 out of 4 Amsel criteria, resulting in higher reported rates of cure for bacterial vaginosis.

Table 3. Efficacy of Clindesse in Treatment of Bacterial Vaginosis in a Randomized, Investigator-Blind, Active-Controlled Comparative Study – Modified-Intent-to-Treat

Outcome

Clindesse
Single Dose
N=221
% Cure

Clindamycin
Vaginal Cream
(7 doses) N=211
% Cure

Treatment
Difference† (%)
[95% Confidence Interval]

Therapeutic Cure

33.0

37.0

-3.9 [-12.9, 5.1]

Clinical Cure

53.4

54.0

-0.6 [-10.0, 8.8]

Nugent Score Cure

45.7

49.3

-3.6 [-13.1, 5.8]

†Treatment difference = Clindesse minus clindamycin vaginal cream cure rates

N = number of patients in treatment group (modified intent-to-treat population defined as all subjects randomized who received at least one dose of study medication, and who had a baseline Nugent score of at least 4)

Table 4. Efficacy of Clindesse in Treatment of Bacterial Vaginosis in a Randomized, Investigator-Blind, Active-Controlled Comparative Study – Per Protocol

Outcome

Clindesse
Single Dose
N=126
% Cure

Clindamycin
Vaginal Cream
(7 doses) N=125
% Cure

Treatment
Difference† (%)
[95% Confidence Interval]

Therapeutic Cure

42.1

45.6

-3.5 [-15.8, 8.7]

Clinical Cure

64.3

63.2

1.1 [-10.8, 13.0]

Nugent Score Cure

56.5‡

57.7‡

-1.3 [-13.6, 11.1]

†Treatment difference = Clindesse minus clindamycin vaginal cream cure rates

N = number of patients in treatment group (per protocol population defined as all subjects included in the modified intent-to-treat population who completed the study without significant protocol violation)

‡Four subjects (2 from each treatment group) did not have complete Nugent scores and were not included in the Nugent Score cure analysis

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Clindesse (clindamycin phosphate) Vaginal Cream, 2%, is available in cartons containing one single-dose, pre-filled disposable applicator (NDC 45802-042-01). Each applicator delivers approximately 5 g of vaginal cream containing approximately 100 mg of clindamycin.

Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature.]

Avoid heat above 30°C (86°F).

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Vaginal Intercourse and Use with Vaginal Products

Instruct the patient not to engage in vaginal intercourse, or use other vaginal products (such as tampons or douches) during treatment with this product.

Use with Condoms and Vaginal Contraceptive Diaphragms

Advise the patient that Clindesse contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, do not use barrier contraceptives concurrently or for 5 days following treatment with Clindesse. During this time period, condoms may not be reliable for preventing pregnancy or for protecting against transmission of HIV and other sexually transmitted diseases [see Warnings and Precautions (5.2) and Use in Specific Populations (8.3)].

Fungal Vaginal Infections

Inform the patient that vaginal fungal infections can occur following use of Clindesse and may require treatment with an antifungal drug [see Adverse Reactions (6.1)].

Accidental Exposure to the Eye

Inform the patient that Clindesse contains ingredients which cause burning and irritation of the eye. In the event of accidental contact with the eye, rinse the eye with copious amounts of cool tap water and consult a physician.

Manufactured by Padagis®
Yeruham, Israel

Patents at www.padagis.com/patents

Cleocin is a registered trademark of Pharmacia & Upjohn Company.

2S000 RC PH7

Patient Information

SPL PATIENT PACKAGE INSERT SECTION

PATIENT INFORMATION

Clindesse (clin-DESS)

(clindamycin phosphate)

Vaginal Cream, 2%

Important Information: Clindesse is for intravaginal use only. Do not use in the eyes, mouth, or on your skin.

What is Clindesse?

•  Clindesse vaginal cream is a prescription medicine used to treat bacterial vaginal infections in women who are not pregnant.

•  It is not known if Clindesse is safe and effective in females who have not yet reached puberty.

Do not use Clindesse if you:

•  are allergic to clindamycin or other lincosamide antibiotic medicines or are allergic to any of the ingredients in Clindesse. See the end of this leaflet for a complete list of ingredients in Clindesse.

•  have had bowel problems such as:

    ◦  inflammation of your intestines (enteritis)

    ◦  inflammation of your colon (colitis)

    ◦  diarrhea due to a Clostridioides difficile-associated diarrhea (CDAD)

Before using Clindesse, tell your healthcare provider about all of your medical conditions, including if you:

•  are pregnant or plan to become pregnant. It is not known if Clindesse will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with Clindesse.

•  are breastfeeding or plan to breastfeed. The amount of Clindesse which passes into your breast milk is low and is not expected to harm your baby. Talk with your healthcare provider about the best way to feed your baby while using Clindesse.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use Clindesse?

•  Use Clindesse exactly as your healthcare provider tells you to use it.

•  Use 1 filled applicator of Clindesse in the vagina at any time of the day.

•  Do not use any medicine from the tube or applicator more than 1 time. Clindesse is for 1 time (single-use) only.

•  Do not use Clindesse in the eyes, mouth, or on your skin. If you accidently get Clindesse in your eyes rinse your eyes with cool tap water right away and call your healthcare provider.

•  See the Instructions for Use at the end of this Patient Information leaflet for more information about how to fill the applicator and use Clindesse.

What should I avoid while using Clindesse?

After you insert Clindesse:

•  Do not have vaginal sex or use vaginal products (such as tampons or douches) during your treatment.

•  Do not use barrier contraceptive products during your treatment or for 5 days after your treatment.

    ◦  Barrier contraceptives include condoms or contraceptive diaphragms used for birth control or to protect yourself against Human Immunodeficiency Virus (HIV) or other sexually transmitted diseases (STDs).

    ◦  Clindesse contains mineral oil that may weaken latex or rubber products in condoms or vaginal contraceptive diaphragms.

    ◦  Condoms or vaginal contraceptive diaphragms may not work as well for preventing pregnancy, or for protecting against HIV and other STDs.

What are the possible side effects of Clindesse?

Clindesse may cause serious side effects, including diarrhea. One type of diarrhea is caused by an infection in your intestines called Clostridioides difficile-associated diarrhea (CDAD), which may range in severity from mild diarrhea to colitis that can lead to death. If you have diarrhea after you use Clindesse, call your healthcare provider.

The most common side effects of Clindesse include:

•  fungal infection in your vagina that may require treatment with an antifungal medicine.

•  headache

•  back pain

•  constipation

•  urinary tract infection

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of Clindesse. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Clindesse?

•  Store Clindesse between 68°F to 77°F (20°C to 25°C).

Keep Clindesse and all medicines out of the reach of children.

General information about the safe and effective use of Clindesse.

Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use Clindesse for a condition for which it was not prescribed. Do not give Clindesse to other people, even if they have the same symptoms you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about Clindesse that is written for health professionals.

What are the ingredients in Clindesse?

Active ingredient: clindamycin phosphate

Inactive ingredients: edetate disodium, glycerol monoisostearate, lecithin, methylparaben, microcrystalline wax, mineral oil, polyglyceryl-3-oleate, propylparaben, purified water, silicon dioxide and sorbitol solution.

For more information, go to www.clindesse.com or call 1-866-634-9120

This Patient Information has been approved by the U.S. Food and Drug Administration

01/2025

Instructions for Use

INSTRUCTIONS FOR USE SECTION

Clindesse (clin-DESS)

(clindamycin phosphate)

Vaginal Cream, 2%

For vaginal use only.

Do not put Clindesse in your eyes, mouth, or on your skin.

It is important that you read and follow these directions on how to use Clindesse vaginal cream properly.

Clindesse comes in a single-dose, pre-filled, disposable applicator that gives you a certain amount of clindamycin cream to be inserted into your vagina.

Step 1. Prepare the applicator.

Peel back the protective foil and remove the pre-filled applicator. Do not remove the tip.

The applicator is made to be used with the tip in place.

Do not use the applicator if the tip has been removed (see Figure 1).

Figures 1 and 2
Figures 1 and 2

Activate the plunger before you use it. To activate the plunger, pull the ring back to fully extend the plunger while you firmly hold the applicator (see Figure 2).

Step 2. Insert the applicator.

Gently insert the applicator into your vagina as far as it will comfortably go (see Figure 3).

Figure 3
Figure 3

Step 3. Apply the cream.

Push the plunger in until all of the cream goes into your vagina (see Figures 4 and 5).

Figures 4 and 5
Figures 4 and 5

Step 4. Remove the empty applicator from your vagina and throw it away in the trash.

This Instructions for Use has been approved by the U.S. Food and Drug Administration

01/2025

Package/Label Display Panel - Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Clindesse®

(clindamycin phosphate) Vaginal Cream, 2%

NDC 45802-042-01

Rx Only

This applicator delivers approximately 5 g of vaginal cream containing approximately 100 mg of clindamycin.

One complete course of therapy in a convenient, prefilled, and disposable applicator.

NET WT 5.8 g

carton
carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309337clindamycin phosphate 2 % Vaginal CreamPSN12
602427Clindesse 2 % Vaginal CreamPSN12
602427clindamycin 20 MG/ML Vaginal Cream [Clindesse]SBD12
309337clindamycin 20 MG/ML Vaginal CreamSCD12
309337clindamycin (as clindamycin phosphate) 2 % Vaginal CreamSY12
309337clindamycin 2 % Vaginal CreamSY12
602427Clindesse (as clindamycin phosphate) 2 % Vaginal CreamSY12
602427Clindesse 2 % Vaginal CreamSY12
602427Clindesse 20 MG/ML Vaginal CreamSY12

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CLINDAMYCIN Pharmacologic Class Indexing3Indexing - Pharmacologic Class20210811

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a46239a7-5963-4008-8cbb-6b9000f497ebProduct name120250721
1426d8f8-b7d5-4053-8554-613df00c0d86Product name220250616
b382b4e1-6b48-45f6-bffc-e61b00b0ce19Product name320250317
d8f81258-db12-0761-46cc-8ff6e62e9302Product name420240422
b7b2fa42-1c77-d724-81f0-87da60a77e79Product name320240320
b27c7c65-51f2-a62f-e0e6-a26b3a0f8eb0Product name320230425
e3af9708-3004-7392-4046-5311eaa8bab5Product name320221128
ffb4bacf-f636-0f7d-0b0d-7a4b151243e3Product name920220928
b72227d6-0388-43bd-995b-b762d2754cd5Product name120220706
a92d22e0-3af4-f301-bc88-27ff030b0070Product name220220316
4a7d44fe-774d-404b-aad0-8a90fe78375aProduct name420211025
d12e2d7c-bd6b-45d4-94f9-6df8e1b8b27bProduct name320200203
ee5c6de5-d9cd-454f-b250-7b19e5cf2992Product name420190619
5ce6ce33-4f2b-3ce0-757d-e520013280cfProduct name520180719
b92a26f1-6926-4817-be73-e26ab4c2146fProduct name120170602
028d6c95-5012-6976-2075-dee0ae6fefe2Product name120140508
468b2c08-8adb-8d0f-8257-c6515a061424Product name120140508
8959fb29-d86f-c521-666a-b4cb22233594Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
45802-042-01Clindesse5 g in 1 APPLICATORCREAM512
45802-042-01Clindesse1 in 1 CARTONCREAM112
45802-042-02Clindesse1 in 1 CARTONCREAM112
45802-042-02Clindesse5 g in 1 APPLICATORCREAM512

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
45802-042-01GM - Gram45802-04283e90ef2-4fea-4214-b68e-1d192d02d69412015-07-20

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CLINDAMYCIN PHOSPHATEACTIVE INGREDIENTEH6D7113I83
CLINDAMYCINACTIVE MOIETY3U02EL437C3
EDETATE DISODIUMINACTIVE INGREDIENT7FLD91C86K3
GLYCERYL ISOSTEARATEINACTIVE INGREDIENTHYE7O27HAO3
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T3
MICROCRYSTALLINE WAXINACTIVE INGREDIENTXOF597Q3KY3
MINERAL OILINACTIVE INGREDIENTT5L8T28FGP3
POLYGLYCERYL-3 OLEATEINACTIVE INGREDIENTXRQ165498B3
PROPYLPARABENINACTIVE INGREDIENTZ8IX2SC1OH3
SORBITOLINACTIVE INGREDIENT506T60A25R3
WATERINACTIVE INGREDIENT059QF0KO0R3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 14 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
45802-04245802-042-01, 45802-042-02

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 24 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
GLYCERYL ISOSTEARATEGLYCERYL ISOSTEARATEHYE7O27HAOCREAM / VAGINAL135 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
GLYCERYL ISOSTEARATEGLYCERYL ISOSTEARATEHYE7O27HAOCREAM / VAGINAL135 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RCREAM / TOPICAL36.8 %w/wExact identifier — unii+dosage form
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCREAM / VAGINAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCREAM / VAGINAL402 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MICROCRYSTALLINE WAXMICROCRYSTALLINE WAXXOF597Q3KYCREAM / VAGINAL23 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCREAM / VAGINAL22 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RCREAM / TOPICAL36.8 %w/wExact identifier — unii+dosage form
3 equally ranked IID candidates
POLYGLYCERYL-3 OLEATEPOLYGLYCERYL-3 OLEATEXRQ165498BCREAM / VAGINAL135 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM / VAGINAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
GLYCERYL ISOSTEARATEGLYCERYL ISOSTEARATEHYE7O27HAOCREAM / VAGINAL135 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM / VAGINAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
POLYGLYCERYL-3 OLEATEPOLYGLYCERYL-3 OLEATEXRQ165498BCREAM / VAGINAL135 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCREAM / VAGINAL402 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCREAM / VAGINAL402 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
POLYGLYCERYL-3 OLEATEPOLYGLYCERYL-3 OLEATEXRQ165498BCREAM / VAGINAL135 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCREAM / VAGINAL22 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MICROCRYSTALLINE WAXMICROCRYSTALLINE WAXXOF597Q3KYCREAM / VAGINAL23 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RCREAM / TOPICAL36.8 %w/wExact identifier — unii+dosage form
3 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM / VAGINAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCREAM / VAGINAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MICROCRYSTALLINE WAXMICROCRYSTALLINE WAXXOF597Q3KYCREAM / VAGINAL23 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCREAM / VAGINAL22 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCREAM / VAGINAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N050793-001CLINDESSECLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30

Orange Book patents#

Current patent rows page 1 of 1 · 1 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N050793-00197890572026-12-02U-137Drug product2018-01-09

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30d4dbc9d85df4…
2026-10-15 13:18:302026-09N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30c2088c7a36db…
2026-09-14 22:38:342026-08N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-3084e616aacf4f…
2026-08-18 06:07:402026-07N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-3031067a03dcf5…
2025-08-23 18:47 UTC2025-08N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-306a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-3003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-302680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-305bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-3079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-301e350fbaab3a…
2024-05-31 18:47 UTC2024-05N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-308072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-305c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-305d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-304b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-3074a2ff9319b5…
2022-03-09 01:35 UTC2022-03N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-3087673890dc5c…
2021-03-12 10:30 UTC2021-03N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-305aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-308869cabd3fbd…
2020-11-12 02:37 UTC2020-11N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30c0c555d07b60…
2019-12-14 00:12 UTC2019-12N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-303f01610625f2…
2019-09-15 20:21 UTC2019-09N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30b00525d2431f…
2019-07-19 19:46 UTC2019-07N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-306a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-301c564ffb4f44…
2023-12-20 04:57 UTC2023-12N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-309b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-303f0d92c62455…
2023-05-13 08:27 UTC2023-05N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-30053a50430f4f…
2023-01-26 05:58 UTC2023-01N050793-001CLINDESSEEQ 2% BASECREAM / VAGINALRLD, RS2004-11-303bdfa0b2c4d7…

Observed Orange Book patent history#

Patent history page 1 of 2 · 69 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-11-14 07:37:172026-10N050793-00197890572026-12-02U-137Drug product2018-01-09d4dbc9d85df4…
2026-10-15 13:18:302026-09N050793-00197890572026-12-02U-137Drug product2018-01-09c2088c7a36db…
2026-09-14 22:38:342026-08N050793-00197890572026-12-02U-137Drug product2018-01-0984e616aacf4f…
2026-08-18 06:07:402026-07N050793-00197890572026-12-02U-137Drug product2018-01-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N050793-00197890572026-12-02U-137Drug product2018-01-09011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N050793-00197890572026-12-02U-137Drug product2018-01-0931067a03dcf5…
2025-08-23 18:47 UTC2025-08N050793-00197890572026-12-02U-137Drug product2018-01-096a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N050793-00197890572026-12-02U-137Drug product2018-01-09fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N050793-00197890572026-12-02U-137Drug product2018-01-09b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N050793-00197890572026-12-02U-137Drug product2018-01-0903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N050793-00197890572026-12-02U-137Drug product2018-01-092680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N050793-00197890572026-12-02U-137Drug product2018-01-095bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N050793-00197890572026-12-02U-137Drug product2018-01-09d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N050793-00197890572026-12-02U-137Drug product2018-01-09d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N050793-00197890572026-12-02U-137Drug product2018-01-0979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N050793-00197890572026-12-02U-137Drug product2018-01-09301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050793-00197890572026-12-02U-137Drug product2018-01-091e350fbaab3a…
2024-05-31 18:47 UTC2024-05N050793-00197890572026-12-02U-137Drug product2018-01-098072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050793-00168998902023-04-27U-137Drug product5c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050793-00197890572026-12-02U-137Drug product2018-01-095c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N050793-00168998902023-04-27U-137Drug product5d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N050793-00197890572026-12-02U-137Drug product2018-01-095d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N050793-00168998902023-04-27U-137Drug product4b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N050793-00197890572026-12-02U-137Drug product2018-01-094b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N050793-00168998902023-04-27U-137Drug product74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N050793-00197890572026-12-02U-137Drug product2018-01-0974a2ff9319b5…
2022-03-09 01:35 UTC2022-03N050793-00168998902023-04-27U-137Drug productbb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N050793-00197890572026-12-02U-137Drug product2018-01-09bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N050793-00168998902023-04-27U-137Drug product782e0a99824c…
2021-12-28 21:50 UTC2021-12N050793-00197890572026-12-02U-137Drug product2018-01-09782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N050793-00168998902023-04-27U-137Drug product87673890dc5c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N050793-00197890572026-12-02U-137Drug product2018-01-0987673890dc5c…
2021-03-12 10:30 UTC2021-03N050793-00168998902023-04-27U-137Drug product5aa47cf7b7d7…
2021-03-12 10:30 UTC2021-03N050793-00197890572026-12-02U-137Drug product2018-01-095aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N050793-00168998902023-04-27U-137Drug product8869cabd3fbd…
2020-12-22 03:56 UTC2020-12N050793-00197890572026-12-02U-137Drug product2018-01-098869cabd3fbd…
2020-11-12 02:37 UTC2020-11N050793-00168998902023-04-27U-137Drug productc0c555d07b60…
2020-11-12 02:37 UTC2020-11N050793-00197890572026-12-02U-137Drug product2018-01-09c0c555d07b60…
2019-12-14 00:12 UTC2019-12N050793-00168998902023-04-27U-137Drug product3f01610625f2…
2019-12-14 00:12 UTC2019-12N050793-00197890572026-12-02U-137Drug product2018-01-093f01610625f2…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ClindesseCLINDAMYCIN PHOSPHATEPadagis Israel Pharmaceuticals Ltdfe8bb204-f173-44fe-803b-b08f2ec5aa312025-01-30Warnings, Adverse reactionsExact identifier
ndc (package): 45802-042-01
ndc (package): 45802-042-02
ndc (product): 45802-042
ndc11 (package): 45802004201
ndc11 (package): 45802004202
spl id: ab0a6fe2-5ee0-408c-9e1d-30ce29344d16
spl set id: fe8bb204-f173-44fe-803b-b08f2ec5aa31

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.